Serum Lipid Profiles, Blood Glucose, and High-Sensitivity C-Reactive Protein Levels Among People Living with HIV Taking Dolutegravir and Ritonavir-Boosted Atazanavir-Based Antiretroviral Therapy at Jimma University Medical Center, Southwest Ethiopia, 2021.

Autor:	Waritu NC; Department of Biomedical Sciences, School of Medicine, Wolaita Sodo University, Wolaita Sodo, Ethiopia., Nair SKP; Department of Biomedical Sciences, School of Medicine, Jimma University, Jimma, Ethiopia., Birhan B; Department of Biomedical Sciences, School of Medicine, Jimma University, Jimma, Ethiopia., Adugna T; Department of Biomedical Sciences, School of Medicine, Jimma University, Jimma, Ethiopia., Awgichew GB; Department of Biomedical Sciences, School of Medicine, Jimma University, Jimma, Ethiopia., Jemal M; Department of Biomedical Sciences, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Jazyk:	angličtina
Zdroj:	HIV/AIDS (Auckland, N.Z.) [HIV AIDS (Auckl)] 2024 Feb 12; Vol. 16, pp. 17-32. Date of Electronic Publication: 2024 Feb 12 (Print Publication: 2024).
DOI:	10.2147/HIV.S430310
Abstrakt:	Background: Long-term use of antiretroviral therapy, especially dolutegravir and boosted-atazanavir, raises concerns about cardiovascular disease. Thus, this study aimed to assess lipid profiles, blood glucose, and high-sensitivity C-reactive protein levels among people living with HIV on dolutegravir and ritonavir-boosted atazanavir-based therapy. Methods: An institutional-based comparative cross-sectional study was conducted from November 4, 2021, to January 4, 2022. An equal number of dolutegravir- and ritonavir-boosted atazanavir-treated patients (n = 64 each) was enrolled. A consecutive sampling was used to select participants. The Chi-square, Student's t -test, Mann-Whitney U -test, and logistic regression were used as appropriate statistical tests using SPSS Version 25.0. Statistical significance was set at p < 0.05. Results: Dyslipidemia was found in 67.2% (43/64) of ritonavir-boosted atazanavir group and 48.4% (31/64) of dolutegravir group. The dolutegravir group had significantly higher mean and median values of high-density lipoprotein and random blood sugar, respectively, as well as lower median triglyceride and high-sensitivity C-reactive protein levels than the ritonavir-boosted atazanavir group. Ritonavir-boosted atazanavir-based regimens (AOR=3.4, 95% CI: 1.5, 8) and age >40 years were predictors of dyslipidemia, while BMI ≥25 kg/m 2 (AOR=3.7, 95% CI: 1.3, 10.8) and dolutegravir-based regimens (AOR=4.6, 95% CI: 1.5, 14) were predictors of hyperglycemia. Ritonavir-boosted atazanavir-based regimens (ARR=3, 95% CI: 1.3, 8) and BMI ≥25 kg/m 2 (ARR=2.5, 95% CI: 1.1, 6) were associated with increased high-sensitivity C-reactive protein by 1-3 mg/L. The risk of increased high-sensitivity C-reactive protein by >3 mg/L was greater in those patients with a CD4 cell count of <500 cells/mm 3 (ARR=5, 95% CI: 1.1, 24). Conclusion: When compared to ritonavir-boosted atazanavir-based regimens, dolutegravir had favorable lipid profiles and high-sensitivity C-reactive protein but unfavorable blood glucose levels. Therefore, baseline blood glucose, lipid profiles, and high-sensitivity C-reactive protein levels should be routinely measured in patients on these regimens. Competing Interests: The authors declare that they have no competing interests in this work. (© 2024 Waritu et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu